Nicoline Hoogerbrugge - Genetic Mutations

Author Information

Nicoline Hoogerbrugge is affiliated with the Department of Human Genetics at the Radboud University Medical Center, located in Nijmegen, The Netherlands. She has made significant contributions to the field of genetics, particularly in relation to hereditary cancer syndromes.

Research Contributions

Nicoline Hoogerbrugge's research focuses on hereditary cancer syndromes, including the genetic predisposition to various cancers such as ovarian, breast, and gastrointestinal tumors. Her work has led to a better understanding of the risks associated with specific genetic mutations, as well as the development of preventive strategies. Notable publications from 2021 and 2022 include studies on the risk of peritoneal carcinomatosis post-surgery, the implications of germline MBD4 deficiency, and cancer worry among BRCA1/2 pathogenic variant carriers. She also contributes to enhancing clinical networks for rare diseases and solving the genetic etiology of hereditary gastrointestinal tumor syndromes.

Aliases

Nicoline Hoogerbrugge is also known by several aliases, including N Hoogerbrugge, N. Hoogerbrugge, and Nicolin Hoogerbrugge.

Publication and Citation Metrics

Metric	Value
Citation Count	15,174
h-index	64
Paper Count	363

Publications:

Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.

DOI: 10.1200/JCO.21.02016

Year: 2022

Germline MBD4 deficiency causes a multi-tumor predisposition syndrome.

DOI: 10.1016/j.ajhg.2022.03.018

Year: 2022

Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors

DOI: 10.1007/s00520-021-06726-4

Year: 2022

Enhancing the value of clinical networks for rare diseases

DOI: 10.20517/rdodj.2022.01

Year: 2022

Solving the genetic aetiology of hereditary gastrointestinal tumour syndromes- a collaborative multicentre endeavour within the project Solve-RD.

DOI: 10.1016/j.ejmg.2022.104475

Year: 2022

Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.

DOI: 10.1016/j.ygyno.2021.10.072

Year: 2021

Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.

DOI: 10.1016/j.ygyno.2021.08.019

Year: 2021

Red flags for early recognition of adult patients with PTEN Hamartoma Tumour Syndrome.

DOI: 10.1016/j.ejmg.2021.104364

Year: 2021

Continue rare cancers collaboration with European Reference Networks after Brexit

DOI: 10.1016/S0140-6736(21)00264-6

Year: 2021

Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe.

DOI: 10.1016/j.ejmg.2021.104350

Year: 2021

What Future Research is Needed?

What is the Future of Genetic Research?

Can These Errors Be Prevented?

What are DNA Molecules?

What are the Challenges in Data Analysis?

How Do Genetic Mutations Affect Vaccine Efficacy?

How Do Occupational Therapists Use Genetic Information?

How Does Hemoglobin Electrophoresis Work?

How do Genetic Mutations Affect Health?

What is Prenatal Screening?

Partnered Content Networks

Relevant Topics